{
    "organizations": [],
    "uuid": "1243b1502a2070d2e910f4b1b5bc680734c98caf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-chiasma-announces-fda-agreement-to/brief-chiasma-announces-fda-agreement-to-redefine-certain-secondary-endpoints-in-phase-3-clinical-trial-idUSASC0A22I",
    "ord_in_thread": 0,
    "title": "BRIEF-Chiasma Announces FDA Agreement To Redefine Certain Secondary Endpoints In Phase 3 Clinical Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 14 (Reuters) - Chiasma Inc:\n* CHIASMA ANNOUNCES FDA AGREEMENT TO REDEFINE CERTAIN SECONDARY ENDPOINTS IN CHIASMA OPTIMAL PHASE 3 CLINICAL TRIAL\n* CHIASMA - FOURTH, FIFTH SECONDARY ENDPOINTS IN PHASE 3 TRIAL NOW BEEN REDEFINED TO DESCRIPTIVE STATISTICS MEASURED WITHIN EACH TREATMENT GROUP\n* CHIASMA INC - UNDER SPA AGREEMENT MODIFICATION FOR CHIASMA OPTIMAL PHASE 3 TRIAL, BETWEEN-ARM COMPARISONS OF 2 DESCRIPTIVE MEASURES WILL NOT BE MADE\n* CHIASMA INC - FDA INDICATED IT PLANS TO CONSIDER SECONDARY ENDPOINTS IN ITS EVALUATION OF TOTALITY OF EVIDENCE OF ORAL OCTREOTIDEâ€™S TREATMENT EFFECT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-15T04:23:00.000+03:00",
    "crawled": "2018-05-15T13:58:08.057+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "chiasma",
        "inc",
        "chiasma",
        "announces",
        "fda",
        "agreement",
        "redefine",
        "certain",
        "secondary",
        "endpoint",
        "chiasma",
        "optimal",
        "phase",
        "clinical",
        "trial",
        "chiasma",
        "fourth",
        "fifth",
        "secondary",
        "endpoint",
        "phase",
        "trial",
        "redefined",
        "descriptive",
        "statistic",
        "measured",
        "within",
        "treatment",
        "group",
        "chiasma",
        "inc",
        "spa",
        "agreement",
        "modification",
        "chiasma",
        "optimal",
        "phase",
        "trial",
        "comparison",
        "descriptive",
        "measure",
        "made",
        "chiasma",
        "inc",
        "fda",
        "indicated",
        "plan",
        "consider",
        "secondary",
        "endpoint",
        "evaluation",
        "totality",
        "evidence",
        "oral",
        "octreotide",
        "treatment",
        "effect",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}